ProCE Banner Activity

Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies

Slideset Download

Get up to date on individualizing therapy with BTK inhibitors for the management of chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma by considering patient characteristics and the unique safety profile of available BTK inhibitors.

Released: October 11, 2023



Matthew S. Davids

Matthew S. Davids, MD, MMSc

Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Josie Montegaard

Josie Montegaard, MSN, AGPCNP-BC

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner


Supported by an educational grant from AstraZeneca.